Randomized Clinical Trial
Copyright ©The Author(s) 2018.
World J Gastroenterol. Mar 28, 2018; 24(12): 1361-1372
Published online Mar 28, 2018. doi: 10.3748/wjg.v24.i12.1361
Table 2 SVR12 in hepatitis C virus genotype 1b-infected patients with and without resistance-associated polymorphisms at baseline (immediate treatment arm) n (%)
All patients - immediate treatment arm
With RAPs at baseline
Without RAPs at baseline
Mainland ChinaRussiaSouth KoreaOverallMainland ChinaRussiaSouth KoreaOverall
NS5A-L31M/V1/1 (100)1/1(100)02/2 (100)108/117 (92.3)21/22 (95.5)10/13 (76.9)139/152 (91.4)
Y93H7/13(53.8)00/2 (0)7/15 (46.7)102/105 (97.1)22/23 (95.7)10/11(90.9)134/139 (96.4)
L31M/V or Y93H8/14 (57.1)1/1 (100)0/2 (0)9/17 (52.9)101/104 (97.1)21/22 (95.5)10/11(90.9)132/137 (96.4)
NS3-D168E0/1 (0)000/1 (0)109/117 (93.2)22/23 (95.7)10/13 (76.9)141/153 (92.2)